Teva VP Ika Abravanel resigns
Assuta will provide limited public services ahead of the full operation of the hospital.
Sources inform ''Globes'' that the Ministry of Health has given Assuta Medical Centers Ltd. permission to begin limited public services at the new Ashdod hospital next year. Assuta, a private hospital, won the tender to build the public hospital, construction of which will be completed in six years. Assuta will not be allowed to provide private medical services in this stage.
Assuta will operate an emergency room in a sheltered structure to protect against missile attacks, an internal medicine ward, a geriatrics ward, pediatrics ward, cardiology center, oncology institute, and dialysis institute.
Assuta will not provide surgical facilities, except for cardiac catheterization. The wards will have 105 beds altogether and an additional 100 beds for up to 24 hour hospitalizations.
The services will be provided in a six-floor building, built by the haredi (ultra-orthodox) NPO Refuah Veyeshua (Medicine and Salvation), which quit the tender, despite investing tens of millions of shekels in it. This facility will have a CT and MRI scanner. The building's underground parking garage can be converted into a hospital during an emergency.
The partial operation of the Ashdod hospital is good news for the city's 230,000 residents, and will happen ten years after the Knesset passed the law ordering the construction of a public hospital in the city. More interestingly, however, is that the Ministry of Health comes one week after the government was forced to respond to a petition filed with the High Court of Justice by several NPOs against Assuta providing private services at the hospital. The petitioners, including the Association for Civil Rights in Israel and Physicians for Human Rights, contended that the operation of a private hospital contravened the principle of equality stipulated in the Health Insurance Law. The government argued in response that the right to provide a quarter of the surgical procedures on a private basis was the reason Assuta bid in the tender, and without this clause, it is liable to withdraw from the project.
Sources inform ''Globes'' that Ministry of Health director general Prof. Ronny Gamzo is not a party to the government's position that was presented to the High Court of Justice. He believes that the Ashdod hospital is economically viable without the provision of private medical services. It is possible by allowing Assuta to provide limited public medical services at the hospital is intended to demonstrate the hospital's viability without private services to Assuta and the Ministry of Finance, in addition to helping meet the medical needs of Ashdod's residents.
Published by Globes [online], Israel business news - www.globes-online.com - on April 11, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
You comment was recieved and soon will be published.
Load more comments
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.